Fig. 1 · Structure

Documents & Downloads

Amiloride HCl

Cat. No. A10064 CAS 2016-88-8

Na+ channel blocker

Amiloride hydrochloride is a Na+ channel blocker, also inhibits TRPP3 channels and Na+/H+ exchanger (NHE).

In Stock

Publications for Amiloride HCl

2 publications citing this product

  1. Yu Y, .et al. , Cell Physiol Biochem, 2019, 52(5):1017-1038 PMID: 30977986
  2. Thomas D. Williams, .et al. , J Cell Sci, 2018, Mar 15; 131(6): jcs213736 PMID: 29440238

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Amiloride inhibits epithelial sodium channel (ENaC) activity. In HEK293T/17 cells expressing tagged human αβγ ENaC, amiloride hydrochloride hydrate inhibited Na+ current with an IC50 of 86.34 ± 27.04 nM at −60 mV (mean ± SEM; five independent experiments). The study found no voltage dependence across −60 to 0 mV. These results describe the amiloride active moiety; the tested hydrated material differs from the catalog anhydrous hydrochloride form. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Amiloride HCl Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Amiloride HCl from 2 published references.

Amiloride HCl In Vitro Studies

Concentration-dependent inhibition of human ENaC current

Cell-based study · HEK293T/17 cells expressing human αβγ ENaCeGFP; all three wild-type subunits bear N-terminal tags. [1]

Amiloride inhibited ENaC-mediated Na+ current. Reported IC50 values were similar across holding potentials from −60 to 0 mV; the authors found no voltage dependence over this range. These are functional cellular measurements, not binding affinities.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of blocker-sensitive Na+ current through tagged human αβγ ENaCIC50 −60 mV: 86.34 ± 27.04 nM; −40 mV: 80.25 ± 11.37 nM; −20 mV: 80.05 ± 8.78 nM; 0 mV: 97.14 ± 21.62 nM (mean ± SEM; five independent experiments)[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 nM, 10 nM, 100 nM, 1 μM, 10 μM and 100 μM
Method
Extracellular application during whole-cell patch-clamp recording in 150 mM NaCl solution, pH 7.4; holding potentials −60, −40, −20 and 0 mV.
Co-treatment
Blockers tested separately. Cells had been maintained with 500 nM phenamil mesylate before recording; the recording dose-response solutions are described separately.
Reported limits
Duration per concentration and stock solvent not specified in the selected recording description. Exact hydration stoichiometry not supplied. Pretreatment conditions should be considered when transferring this assay.
Methods and source locations

Compound reported in the paper: Amiloride hydrochloride hydrate; Compound label in the paper: Amiloride

Molar pharmacology of amiloride in a recombinant cellular model; the reported material was hydrochloride hydrate, not verified A10064.

Table 1 (amiloride column, IC50 values in nM); Figure 1—figure supplement 1h–i and caption; Materials and methods: key resources table, Construct design, Whole cell patch clamp experiments

Inhibition of blocker-sensitive Na+ current through tagged human αβγ ENaC: Whole-cell patch clamp in HEK293T/17 cells expressing ENaCeGFP. Blocker-sensitive current defined using 100 μM blocker and normalized to the no-blocker response. IC50 measured at four holding potentials. — Table 1 (amiloride column, IC50 values in nM); Figure 1—figure supplement 1h–i and caption; Materials and methods: key resources table, Construct design, Whole cell patch clamp experiments

Amiloride HCl In Vivo Studies

In wild-type and γENaC RKRK186QQQQ knock-in mice, four days of subcutaneous amiloride produced a transient increase in urinary sodium excretion and reduced body weight. Urinary potassium excretion was reported as unchanged, but plasma potassium increased; plasma sodium remained unchanged. The paper reports amiloride without specifying its salt or hydration state. [2]

Renal responses to four days of amiloride

Animal study · γENaC RKRK186QQQQ knock-in mice and wild-type littermates, 3–6 months old, both sexes. [2]

Repeated amiloride treatment produced an early increase in sodium excretion followed by adaptation in both genotypes. Urinary potassium excretion was reported as unchanged, while plasma potassium rose after four days. Plasma sodium was unchanged and body weight decreased. This is renal pharmacodynamic evidence in a specific mouse model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Urinary sodium excretion during repeated treatmentQualitative reported response Increased on day 1 and returned to normal levels; no difference between genotypes. Figure 1G–I gives n = 3–12 per genotype across the displayed measurements.[2]
Urinary potassium excretion during repeated treatmentQualitative reported response Reported as unchanged during treatment.[2]
Plasma potassium and sodium after four daysQualitative reported response Plasma potassium increased in both genotypes; plasma sodium remained unchanged. Figure 2 gives n = 5–16 (wild type) and n = 5–19 (knock-in) across the displayed conditions/endpoints; exact amiloride-arm n not recovered.[2]
Body weight during repeated treatmentQualitative reported response Decreased significantly in both genotypes and reached a lower steady state.[2]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Twice daily
Treatment course
4 days
Vehicle
Injectable water; amiloride solution 2 mg/mL
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
γENaCwt/wt wild-type littermates
10 μg/g body weight per injection
Pretreatment/control values; Figure 1 day-0 control data pooled from experimental series. No separate four-day vehicle regimen specified in selected text.Transient increase in sodium excretion, no reported change in urinary potassium excretion, reduced body weight and increased plasma potassium; plasma sodium unchanged.[2]
γENaCki/ki (RKRK186QQQQ) knock-in mice
10 μg/g body weight per injection
Pretreatment/control values; Figure 1 day-0 control data pooled from experimental series. No separate four-day vehicle regimen specified in selected text.Transient increase in sodium excretion, no reported change in urinary potassium excretion, reduced body weight and increased plasma potassium; plasma sodium unchanged.[2]
γENaCwt/wt wild-type littermates
Model: 3–6-month-old mice of both sexes; γENaCwt/wt wild-type littermates
Reported limits: Exact salt/hydration and supplier catalog number unspecified. Endpoint-specific n and sex breakdown in Table S2 were not retrieved; plotted n ranges retained in measurements.
γENaCki/ki (RKRK186QQQQ) knock-in mice
Model: 3–6-month-old mice of both sexes; γENaCki/ki (RKRK186QQQQ) knock-in mice
Reported limits: Exact salt/hydration and supplier catalog number unspecified. Endpoint-specific n and sex breakdown in Table S2 were not retrieved; plotted n ranges retained in measurements.
Methods and source locations

Compound reported in the paper: Amiloride; Compound label in the paper: Amiloride (salt/hydration unspecified)

Reported amiloride pharmacodynamics, with unspecified salt form. No Adooq validation or product-specific dose recommendation.

Sections 2.2.2, 2.2.3 and 2.2.6; Section 3.1, repeated amiloride paragraph; Figure 1G–I and caption; Section 3.2; Figure 2A–B and caption

Urinary sodium excretion during repeated treatment: Urinary Na+/K+ by flame photometry; 24 h excretion normalized to urinary creatinine and food intake. Plasma electrolytes measured with a blood gas analyzer. — Section 3.1; Figure 1G and caption; Sections 2.2.3 and 2.2.6

Urinary potassium excretion during repeated treatment: Urinary Na+/K+ by flame photometry; 24 h excretion normalized to urinary creatinine and food intake. Plasma electrolytes measured with a blood gas analyzer. — Section 3.1; Figure 1H and caption; Sections 2.2.3 and 2.2.6

Plasma potassium and sodium after four days: Urinary Na+/K+ by flame photometry; 24 h excretion normalized to urinary creatinine and food intake. Plasma electrolytes measured with a blood gas analyzer. — Section 3.2; Figure 2A–B and caption; Sections 2.2.3 and 2.2.6

Body weight during repeated treatment: Urinary Na+/K+ by flame photometry; 24 h excretion normalized to urinary creatinine and food intake. Plasma electrolytes measured with a blood gas analyzer. — Section 3.1; Figure 1I and caption; Sections 2.2.3 and 2.2.6

γENaCwt/wt wild-type littermates · Sections 2.2.2, 2.2.3 and 2.2.6; Section 3.1, repeated amiloride paragraph; Figure 1G–I and caption; Section 3.2; Figure 2A–B and caption

γENaCki/ki (RKRK186QQQQ) knock-in mice · Sections 2.2.2, 2.2.3 and 2.2.6; Section 3.1, repeated amiloride paragraph; Figure 1G–I and caption; Section 3.2; Figure 2A–B and caption

Specifications

Manufacturer Adooq Bioscience
Actions Blocker
CAS Number 2016-88-8
Applications Na+ channel blocker
Formula C6H9Cl2N7O
Molecular Weight 266.1
Synonyms MK 870; Midamor; Colectril; Amipramizide; Guanamprazine hydrochloride
SMILES
C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 49 mg/mL (184.15 mM)
Water 6 mg/mL (22.54 mM)
Ethanol 5 mg/mL (18.79 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Amiloride HCl Research References

  1. [1] Noreng S, Posert R, Bharadwaj A, et al. Molecular principles of assembly, activation, and inhibition in epithelial sodium channel. eLife (2020). PMID: 32729833 DOI: 10.7554/elife.59038 Source material
  2. [2] Essigke D, Kalo MZ, Wörn M, et al. Hyperaldosteronism in Mice Lacking the Distal Polybasic Tract of the γ-Subunit of the Epithelial Sodium Channel During Sodium Restriction. Acta physiologica (Oxford, England) (2026). PMID: 42037165 DOI: 10.1111/apha.70228 Source material

Publications

2 publications citing this product

  1. Yu Y, .et al. , Cell Physiol Biochem, 2019, 52(5):1017-1038 PMID: 30977986
  2. Thomas D. Williams, .et al. , J Cell Sci, 2018, Mar 15; 131(6): jcs213736 PMID: 29440238

Added to your cart

View Cart Checkout
Loading...